Gastric duodenal metaplasia in duodenal adenomas
- Correspondence to: Dr C A Rubio Gastrointestinal and Liver Pathology Research Laboratory, Department of Pathology, Karolinska Institute and University Hospital, Stockholm 17176, Sweden;
- Accepted 29 June 2006
- Published Online First 12 July 2006
Backgound: In cases of known aetiology, gastric duodenal metaplasia (GMD) is a reversible lesion. In cases of unknown aetiology, the fate of GMD remains elusive. GMD was recently found in a duodenal adenoma.
Aim: To audit the frequency of GMD occurring in a cohort of duodenal adenomas.
Methods: Filed H&E-stained sections from 306 consecutive duodenal adenomas were investigated for the presence of GMD.
Results: 68% of the adenomas (n = 208) were from patients with familial adenomatous polyposis (FAP), and the remaining 32% (n = 98) were sporadic. GMD was found in 31.7% (66/208) of the duodenal FAP adenomas and in 59.2% (58/98) of the duodenal sporadic adenomas (p<0.05). The causes for this difference are elusive.
Conclusions: As for other metaplasias of the gastrointestinal tract (intestinal metaplasia of the oesophagus and of the stomach, and metaplastic–hyperplastic polyposis of the colon, known to antedate neoplastic transformation), a subset of GMDs of unknown cause might be present in the duodenal mucosa before adenomatous changes ensue. That subset of GMD might have neoplastic proclivity similar to the metaplastic epithelium in other organs of the gastrointestinal tract. The known carcinogenic effect of high concentrations of bile acids and pancreatic juices bathing the duodenal mucosa carrying an irreversible subset of GDM might set aflame the adenomatous neoplastic transformation in these patients.
- FAP, familial adenomatous polyposis
- GMD, gastric metaplasia in the duodenum
- PAS, periodic acid-Schiff
Published Online First 12 July 2006
Competing interests: None declared.